Stock 603858 SHANDONG BUCHANG PHARMACEUTICALS CO., LTD.
Add to a list
To use this feature you must be a member
Log inSign up

Highlights Shandong Buchang Pharmaceuticals Co., Ltd.

Equities

603858

CNE100002FV6

End-of-day quote Shanghai S.E.
Other stock markets
 23:00:00 14/05/2024 BST 		5-day change 1st Jan Change
16.6 CNY -1.72% Intraday chart for Shandong Buchang Pharmaceuticals Co., Ltd. -1.54% -2.41%
04-25 Shandong Buchang Pharmaceuticals Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
04-25 Shandong Buchang Pharmaceuticals Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023 CI

Highlights

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Shandong Buchang Pharmaceuticals Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024
CI
Shandong Buchang Pharmaceuticals Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023
CI
Tranche Update on Shandong Buchang Pharmaceuticals Co., Ltd.'s Equity Buyback Plan announced on December 14, 2023.
CI
Buchang Pharma Obtains Green Light to Trial Gastric Cancer Drug Combination
MT
Tranche Update on Shandong Buchang Pharmaceuticals Co., Ltd.'s Equity Buyback Plan announced on December 14, 2023.
CI
Shandong Buchang Pharmaceuticals Co., Ltd. announces an Equity Buyback for CNY 360 million worth of its shares.
CI
Shandong Buchang Pharmaceuticals Co., Ltd. authorizes a Buyback Plan.
CI
Buchang Pharma's Unit Gets Nod to Test Colorectal Cancer Drug
MT
Shandong Buchang Pharmaceuticals Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2023
CI
Haikou Xinyingyang Investment Partnership Enterprise (Limited Partnership) and Xi Chong agreed to acquire 14% stake in Buchang Health Industry (Zhejiang ) Co., Ltd. from Shandong Buchang Pharmaceuticals Co., Ltd.,Hu Cunchao, Li Hui, and Hu Cunchao for CNY 0.
CI
Shandong Buchang Pharmaceuticals Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023
CI
Selling Expenses of Chinese Listed Pharma Companies About 1.5x Higher Than Net Profits in 2022
MT
Buchang Pharmaceuticals to Set Up Medical Device Subsidiary
MT
Buchang Pharma Unit Gets Nod to Make Amendments to Diabetes Drug
MT
Buchang Pharma's Unit Passes Regulator's Good Manufacturing Practice Evaluation
MT
Zhao Yunhua agreed to acquire a 90% stake in Buchang Taoyiyun Health Technology Co., Ltd. from Shandong Buchang Pharmaceuticals Co., Ltd. for CNY 1.
CI
Buchang Pharma Unit Passes Regulatory Inspection
MT
Buchang Pharma Unit Gets Nod for Flu Vaccine Trials in China
MT
Shandong Buchang Pharmaceuticals Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2022
CI
Shandong Buchang Pharmaceuticals Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023
CI
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. 603858 Stock
  4. News Shandong Buchang Pharmaceuticals Co., Ltd.
  5. Highlights